Indentification of Several Kinds of Post-Translational Modifications in Recombinant Protein Pharmaceuticals Using MS/MS
TAO Lei, DING You-xue, LIU Lan, LI Yong-hong, FAN Wen-hong, RAO Chun-ming*, WANG Jun-zhi*
National Institute for Food and Drug Control, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Beijing 100050, China
Abstract��OBJECTIVE To identify several kinds of post-translational modifications in recombinant protein pharmaceuticals by MS/MS. METHODS Firstly the proteins were digested with enzymes, and the obtained peptides were analyzed by UPLC-MS. By MS analysis, peptides with post-translational modifications could be detected, then it was then identified by MS/MS. RESULTS Using MS/MS, the disulfide bonds, peptides with similar molecular mass, O-glycosylation site and the type of N-linked oligosaccharides were identified. CONCLUSION MS/MS analysis can make up for the deficiency of enzyme digestion in some extent, and provide more sufficient evidence for the identification of post-translational modifications.
����,����ѧ,����,������,���ĺ�,�Ĵ���,����־. Ӧ�ô��������������������鵰��ҩ��ķ��������[J]. �й�ҩѧ��־, 2015, 50(19): 1726-1730.
TAO Lei, DING You-xue, LIU Lan, LI Yong-hong, FAN Wen-hong, RAO Chun-ming, WANG Jun-zhi. Indentification of Several Kinds of Post-Translational Modifications in Recombinant Protein Pharmaceuticals Using MS/MS. Chinese Pharmaceutical Journal, 2015, 50(19): 1726-1730.
CORREA A,OPPEZZO P. Overcoming the solubility problem in E. coli: Available approaches for recombinant protein production [J]. Methods Mol Biol,2015, 1258:27-44.
[2]
ROUTLEDGE S J,CLARE M. Setting up a bioreactor for recombinant protein production in yeast [J]. Methods Mol Biol,2012, 866:99-113.
[3]
COX M M. Recombinant protein vaccines produced in insect cells [J]. Vaccine,2012, 30(10):1759-1766.
[4]
LAI T,YANG Y, NG S K. Advances in mammalian cell line development technologies for recombinant protein production [J]. Pharmaceuticals (Basel),2013, 6(5):579-603.
[5]
HOPKINS R F, WALL V E,ESPOSITO D. Optimizing transient recombinant protein expression in mammalian cells [J]. Methods Mol Biol,2012, 801:251-268.
[6]
QIAN X,KRAFT J,NI Y, et al. Production of recombinant human proinsulin in the milk of transgenic mice [J]. Sci Rep,2014, 4:6465.
[7]
WANG J Z. Development and Quality Control of Biopharmaceuticals(���＼��ҩ���о���������������) [M]. Beijing:Science Press, 2007:35-61.
[8]
ROMEO M M,KO B,KIM J, et al. Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(��) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC [J]. Virology, 2015,476:271-288.
[9]
WRIGHTON K H. Protein folding:Phosphorylation regulates IDP folding [J]. Nat Rev Mol Cell Biol,2015, 16(2):66.
[10]
SUGIURA T,MARUYAMA H B. Factors influencing expression and post-translational modification of recombinant protein C [J]. J Biotechnol,1992, 22(3):353-360.
[11]
PARK J H, WANG Z, JEONG H J, et al. Enhancement of recombinant human EPO production and glycosylation in serum-free suspension culture of CHO cells through expression and supplementation of 30Kc19 [J]. Appl Microbiol Biotechnol,2012, 96(3):671-683.
[12]
BANKS D D. The effect of glycosylation on the folding kinetics of erythropoietin [J]. J Mol Biol, 2011, 412(3):536-550.
[13]
SU D,ZHAO H,XIA H. Glycosylation-modified erythropoietin with improved half-life and biological activity [J]. Int J Hematol,2010, 91(2):238-244.
[14]
CHUNG S,QUARMBY V,GAO X, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fc�� receptor binding and antibody-dependent cell-mediated cytotoxicity activities [J]. MAbs,2012, 4(3):326-340.
[15]
ZEITLIN L,PETTITT J,SCULLY C, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an ebola virus immunoprotectant [J]. Proc Natl Acad Sci USA,2011, 108(51):20690-20694.
[16]
TAO L, PEI D N, HAN C M, et al. Characterization and comparison of interferon reference standards using UPLC-MS [J]. Acta Pharm Sin(ҩѧѧ��), 2015, 50(1):75-80.
[17]
CAMPBELL M P,ROYLE L,RUDD P M. GlycoBase and autoGU: Resources for interpreting HPLC-Glycan data[J]. Methods Mol Biol, 2015,1273:17-28.
[18]
GOTZ L,ABRAHAMS J L,MARIETHOZ J, et al. GlycoDigest: A tool for the targeted use of exoglycosidase digestions in glycan structure determination[J]. Bioinformatics, 2014,30(21):3131-3133.
2015, Vol. 50 
